|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
XOMA (US) LLC |
| Information provided by: | XOMA (US) LLC |
| ClinicalTrials.gov Identifier: | NCT00034203 |
Purpose
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.
| Condition | Intervention | Phase |
|
Rheumatoid Arthritis |
Drug: efalizumab |
Phase II |
| MedlinePlus related topics: | Rheumatoid Arthritis |
| Drug Information available for: | Efalizumab |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study |
Eligibility
| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Contacts and Locations![]() |
Show 52 Study Locations |
| XOMA (US) LLC |
More Information
| Study ID Numbers: | HURA501 |
| First Received: | April 23, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00034203 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|